Vir Biotechnology (VIR) Equity Income (2021 - 2025)
Historic Equity Income for Vir Biotechnology (VIR) over the last 5 years, with Q3 2025 value amounting to $1.3 million.
- Vir Biotechnology's Equity Income rose 1814.16% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 15987.68%. This contributed to the annual value of -$5.5 million for FY2024, which is 7475.8% up from last year.
- Latest data reveals that Vir Biotechnology reported Equity Income of $1.3 million as of Q3 2025, which was up 1814.16% from -$3.4 million recorded in Q2 2025.
- Over the past 5 years, Vir Biotechnology's Equity Income peaked at $164.1 million during Q3 2021, and registered a low of -$95.0 million during Q1 2022.
- Moreover, its 5-year median value for Equity Income was -$2.7 million (2023), whereas its average is $226470.6.
- The largest annual percentage gain for Vir Biotechnology's Equity Income in the last 5 years was 20819.95% (2025), contrasted with its biggest fall of 89254.08% (2025).
- Quarter analysis of 5 years shows Vir Biotechnology's Equity Income stood at -$26.0 million in 2021, then surged by 134.12% to $8.9 million in 2022, then plummeted by 111.26% to -$1.0 million in 2023, then dropped by 12.8% to -$1.1 million in 2024, then soared by 218.35% to $1.3 million in 2025.
- Its last three reported values are $1.3 million in Q3 2025, -$3.4 million for Q2 2025, and $6.4 million during Q1 2025.